Table 4. Cox regression analyses of the association between both frailty classifications and overall survival.

	Unadjusted			Adjusted model with mGAa		Adjusted model with oncologists classificationa
	N 288	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value
Systematic mGA
mGA-non-frail	148
mGA-frail	140	1.86 (1.36; 2.56)	<0.001	1.61 (1.14; 2.27)	0.007
Oncologists’ assessment
Onc-non-frail	182
Onc-frail	104	1.94 (1.41; 2.66)	<0.001			1.43 (0.97; 2.10)	0.071
Age (continuous)		1.02 (0.99; 1.05)	0.185	1.05 (1.01; 1.09)	0.010	1.06 (1.02; 1.10)	0.002
Gender
Male	162	1b		1b		1b
Female	126	0,64 (0.46; 0.89)	0.007	0.62 (0.41; 0.93)	0.019	0.66 (0.45; 0.98)	0.040
Cancer type
Breast	30	1b		1b		1b
Prostate	56	7.18 (2.20; 23.42)	0.001		n.s.		n.s.
Other gastrointestinal	34	19.31 (5.84; 63.79)	<0.001	6.25 (1.75; 22.32)	0.005	7.59 (2.12; 27.20)	0.002
Lung	59	16.28 (5.05; 52.43)	<0.001	5.17 (1.48; 18.13)	0.010	5.85 (1.67; 20.51)	0.006
Colorectal	83	4.37 (1.34; 14.26)	0.014		n.s.		n.s.
Other	26	8.40 (2.43; 29.05)	0.001		n.s.		n.s.
Stage
Local	73	1b		1b		1b
Locally advanced	55	3.04 (1.69; 5.47)	<0.001		n.s.		n.s.
Metastasised	160	4.63 (2.77; 7.74)	<0.001	1.84 (0.95; 3.58)	0.071	1.77 (0.91; 3.43)	0.094
Treatment
Curative	91	1b		1b		1b
Palliative chemotherapy	126	7.76 (4.67; 12.89)	<0.001	2.54 (1.27; 5.11)	0.009	2.57 (1.28; 5.18)	0.008
Other palliative systemic cancer treatment	51	2.74 (1.49; 5.05)	0.001		n.s		n.s.
Non-systemic palliative treatment	20	9.47 (4.81; 18.67)	<0.001	4.95 (2.31; 10.63)	<0.001	6.01 (2.79; 12.97)	<0.001
ECOG
0–1	244	1b		1b		1b
2–4	43	1.79 (1.20; 2.66)	0.004		n.s.		n.s.

^aCox regression analysis adjusted for age, sex, diagnosis, stage, treatment and ECOG-PS.

^bReference category.

Bold numbers are statistically significant.